Document Type
Article
Publication Title
American Journal of Hypertension
Publisher
Oxford University Press
Rights and Access Note
© The Author(s) 2021.
Publication Date
12-22-2021
First Page
303
Last Page
305
Issue Number
4
Volume Number
35
Abstract/ Summary
Treatment-resistant hypertension is a topic of great importance and the subject of editorial comments in the American Journal of Hypertension. Homocysteine is an intermediate compound in the vitamin regulated One Carbon Methylation pathway which affects glutathione, methionine, and nitric oxide metabolism. Elevated homocysteine, triggered by genetic mutations or insufficient body stores of active vitamins B6, B12, folate, riboflavin, indicates oxidative stress and is associated with impaired nitric oxide synthesis causing small vessel vasoconstriction in the central nervous system. High homocysteine (defined later) is also a risk factor for hypertension.
Repository Citation
Elias, Merrill F. and Brown, Craig J., "New Evidence for Homocysteine Lowering for Management of Treatment-Resistant Hypertension" (2021). Maine-Syracuse Longitudinal Papers. 74.
https://digitalcommons.library.umaine.edu/longitudinal_papers/74
Citation/Publisher Attribution
Merrill F Elias, Craig J Brown, New Evidence for Homocysteine Lowering for Management of Treatment-Resistant Hypertension, American Journal of Hypertension, Volume 35, Issue 4, April 2022, Pages 303–305, https://doi.org/10.1093/ajh/hpab194
DOI
doi.org/10.1093/ajh/hpab194
Version
post-print (i.e. final draft post-refereeing with all author corrections and edits)
Rights Statement
